Vicks Sinex Vapospray recall
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble for the second time in seven months recalls a product in its Vicks Sinex line. In the most recent recall, announced June 24 for Vicks Sinex Vapospray 4-Hour Decongestant - sold before June 2009 as Sinex Nasal Spray or Ultra Fine Mist - P&G said the formulation may not meet the expiration dates on packages. The firm said packages marked with an expiration date prior to June 2013 should be discarded. A spokeswoman said routine testing found the problems, but the firm has not determined the cause. She added P&G has not determined the number of lots or units affected by the recall, but said the product accounts for less than 1.5 percent of Vicks products' U.S. sales. This recall follows the November 2009 recall of Sinex Vapospray 12-Hour Decongestant Ultra Fine Mist after P&G found bacteria in a product made at its plant in Gross Gerau, Germany. ... Scope child-proof caps fail: Malfunctioning child-resistant caps "in a small percentage of bottles" lead to P&G's recall of 1-liter bottles of Scope Original Mint and Scope Peppermint mouthwash in the U.S. and Canada. The firm said June 25 a number 4 is embossed on the bottom of the affected bottles to the right of the recycling symbol. Though P&G said the recall is precautionary and the product in the affected bottles is safe for use, the firm will provide refund coupons
You may also be interested in...
P&G Recalls Mouthwashes, Shuts Down Colombian Manufacturer
Procter & Gamble shut down a Colombian manufacturing site to address findings of bacterial contamination that prompted a recall of mouthwash products in Canada, Latin America, China and other Asian markets.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.